Abstract
DNA damaging agents including anthracyclines, camptothecins and platinum drugs are among most frequently used drugs in the chemotherapeutic routine. Due to their relatively low selectivity for cancer cells, administration of these drugs is associated with adverse side effects, inherent genotoxicity with risk of developing secondary cancers. Development of new drugs, which could be spared of these drawbacks and characterize by improved antitumor efficacy, remains challenging yet vitally important task. These properties are in large part dictated by the selectivity of interaction between the drug and DNA and in this way the studies aimed at elucidating the complex interactions between ligand and DNA represent a key step in the drug development. Studies of the drug-DNA interactions encompass determination of DNA sequence specificity and mode of DNA binding as well as kinetic, dynamic and structural parameters of binding. Here, we consider the types of interactions between small molecule ligands and polynucleotides, how they are affected by DNA sequence and structure, and what is their significance for the antitumor activity. Based on this knowledge, we discuss the wide array of experimental techniques available to researchers for studying drug-DNA interactions, which include absorption and emission spectroscopies, NMR, magnetic and optical tweezers or atomic force microscopy. We show, using the clinical and experimental anticancer drugs as examples, how these methods provide various types of information and at the same time complement each other to provide full picture of drug- DNA interaction and aid in the development of new drugs.
Keywords: Anticancer drug, atomic force microscopy, circular dichroism, DNA, fluorescence, magnetic tweezers, nuclear magnetic resonance.
Current Pharmaceutical Design
Title:Methods for Elucidation of DNA-Anticancer Drug Interactions and their Applications in the Development of New Drugs
Volume: 22 Issue: 44
Author(s): Majus Misiak, Francesco Mantegazza and Giovanni L. Beretta
Affiliation:
Keywords: Anticancer drug, atomic force microscopy, circular dichroism, DNA, fluorescence, magnetic tweezers, nuclear magnetic resonance.
Abstract: DNA damaging agents including anthracyclines, camptothecins and platinum drugs are among most frequently used drugs in the chemotherapeutic routine. Due to their relatively low selectivity for cancer cells, administration of these drugs is associated with adverse side effects, inherent genotoxicity with risk of developing secondary cancers. Development of new drugs, which could be spared of these drawbacks and characterize by improved antitumor efficacy, remains challenging yet vitally important task. These properties are in large part dictated by the selectivity of interaction between the drug and DNA and in this way the studies aimed at elucidating the complex interactions between ligand and DNA represent a key step in the drug development. Studies of the drug-DNA interactions encompass determination of DNA sequence specificity and mode of DNA binding as well as kinetic, dynamic and structural parameters of binding. Here, we consider the types of interactions between small molecule ligands and polynucleotides, how they are affected by DNA sequence and structure, and what is their significance for the antitumor activity. Based on this knowledge, we discuss the wide array of experimental techniques available to researchers for studying drug-DNA interactions, which include absorption and emission spectroscopies, NMR, magnetic and optical tweezers or atomic force microscopy. We show, using the clinical and experimental anticancer drugs as examples, how these methods provide various types of information and at the same time complement each other to provide full picture of drug- DNA interaction and aid in the development of new drugs.
Export Options
About this article
Cite this article as:
Misiak Majus, Mantegazza Francesco and Beretta L. Giovanni, Methods for Elucidation of DNA-Anticancer Drug Interactions and their Applications in the Development of New Drugs, Current Pharmaceutical Design 2016; 22 (44) . https://dx.doi.org/10.2174/1381612822666160831114622
DOI https://dx.doi.org/10.2174/1381612822666160831114622 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Lessons From HIV-1 Gene Therapy in Humanized Mice: Is Targeting Viral Entry the Road to Success?
Current Gene Therapy Molecular Targets of Omega-3 Fatty Acids for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Multiple Functions of Mammalian Germinal Center Kinases
Current Chemical Biology Gene Therapy Strategies Towards Immune Tolerance to Treat the Autoimmune Diseases
Current Gene Therapy Gold(III) Complexes in the Oncological Preclinical Arena: From Aminoderivatives to Peptidomimetics
Current Topics in Medicinal Chemistry An Overview of Nanoformulated Nutraceuticals and their Therapeutic Approaches
Current Nutrition & Food Science Natural Products as a Source of Protein Kinase Activators and Inhibitors
Current Topics in Medicinal Chemistry The Regulatory Role of Both MBNL1 and MBNL1-AS1 in Several Common Cancers
Current Pharmaceutical Design Inhibition of Virulence Factors and Biofilm Formation of <i>Acinetobacter Baumannii</i> by Naturally-derived and Synthetic Drugs
Current Drug Targets QSAR of Pyrazole Oxadiazole Derivatives as s1p1 Agonists Studied by CoMFA, CoMSIA and Docking
Letters in Drug Design & Discovery Recent Progress in the Medicinal Chemistry of γ-Secretase Inhibitors
Current Topics in Medicinal Chemistry In Vivo Performance of a Ruthenium-cyclopentadienyl Compound in an Orthotopic Triple Negative Breast Cancer Model
Anti-Cancer Agents in Medicinal Chemistry Cannabinoids, Immune System and Cytokine Network
Current Pharmaceutical Design The Impact of Fc Receptors on the Development of Autoimmune Diseases
Current Pharmaceutical Design Melatonin and Melatoninergic Drugs as Therapeutic Agents: Ramelteon and Agomelatine, the Two Most Promising Melatonin Receptor Agonists
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Recent Developments in Particulate-Based Vaccines
Recent Patents on Drug Delivery & Formulation Organic Antifungal Drugs and Targets of Their Action
Current Topics in Medicinal Chemistry Microbial Antigenic Pressure and Evolution of the Immune Response: Toward a Better Understanding of the Human Immune System in Health and Disease and Therapeutic Interventions
Endocrine, Metabolic & Immune Disorders - Drug Targets Potential Role of Bioactive Lipids in Rheumatoid Arthritis
Current Pharmaceutical Design Trans-Platinum Complexes in Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry